Module 12 2019

Purpose of the Guidance

To increase the quantity of standardized data submitted to the FDA for both clinical and nonclinical studies

• Non standardized data reduces the agency’s ability to review data efficiently • Limits the ability to automate analysis

The guidance does NOT describe what data should be submitted

• Determined by science and regulation

The Organisation for Professionals in Regulatory Affairs